Purpose: To investigate fundus autofluorescence (FAF) lifetimes in geographic atrophy (GA) with a focus on macular pigment (MP) and foveal sparing. Methods: The study included 35 eyes from 28 patients (mean age 79.2 AE 8.0 years) with GA. A 30°retinal field, centred at the macula, was investigated using fluorescence lifetime imaging ophthalmoscopy (FLIO). The FLIO technology is based on a Heidelberg Engineering Spectralis system. Decays of FAF were detected in a short (498-560 nm, SSC) and long (560-720 nm, LSC) spectral channel. The mean fluorescence lifetime, s m , was calculated from a threeexponential approximation of the FAF decays. Macular optical coherence tomography (OCT) scans as well as fundus photography were recorded. Results: Review of FLIO data reveals specific patterns of significantly prolonged s m in regions of GA (SSC 616 AE 343 ps, LSC 615 AE 154 ps) as compared to non-atrophic regions. Large s m differences between the fovea and atrophic areas correlate with better visual acuity (VA). Shorter s m at the fovea than within other non-atrophic regions indicates sparing, which was identified in 16 eyes. Seventy per cent of patients treated with lutein supplementation showed foveal sparing, whereas the rate among non-supplemented patients was 22%. Conclusion: Using FLIO, we present a novel way to detect foveal sparing, investigate MP, and analyse variability of s m in different foveal regions (including the prognostic valuable border region) in GA. These findings support the potential utility of FLIO in monitoring disease progression. The findings also highlight the possibly protective effect of lutein supplementation, with implication in recording the presence and distributional pattern of MP.
Introduction
Age-related macular degeneration (AMD) is a leading cause of legal blindness, with a global prevalence of 8.69% in individuals aged 45-85 years (Wong et al. 2014) . While drusen and basal linear deposits are known clinical precursors of AMD, the role of lipofuscin in the pathogenesis of AMD is still under debate (Curcio & Millican 1999; Ablonczy et al. 2013; Ach et al. 2014; Gliem et al. 2016) . The progression of AMD over time from early to intermediate and late stages has been studied previously (Joachim et al. 2015) . Late stages are dreaded because of irreversible atrophy of the retinal pigment epithelium (RPE), resulting in scotomas and visual deficits. When atrophy of the RPE results in loss of the central vision, the unfortunate outcome is often legal blindness.
Two forms of AMD can be categorized: 'exudative' and 'non-exudative' AMD. Treatments of exudative forms with intravitreal injections of inhibitors of vascular endothelial growth factor (VEGF) have been well established, whereas currently no promising treatment of non-exudative forms is available (Rosenfeld et al. 2006; SchmidtErfurth et al. 2014; Chaikitmongkol et al. 2016) . The supplementation of retinal carotenoids, such as lutein and zeaxanthin, has been reported to slow progression of the disease [Age-Related Eye Disease Study 2 (AREDS2) Research Group et al. 2014] . Although the mechanism by which supplementation slows progression of disease is not perfectly understood, it is thought that supplementation results in an increase in MP, particularly the carotenoids lutein, zeaxanthin and meso-zeaxanthin. It can be proposed that retinal carotenoids may also play a role in the pathophysiology of the disease.
Geographic atrophy (GA) emerges as the late form of non-exudative AMD (Sunness 1999) . Its development may be related to drusen patterns within the RPE (Sarks 1982; Sarks et al. 1988) . Geographic atrophy (GA), a non-exudative AMD phenomenon, should be distinguished from macular atrophy, the latter of which occurs in patients with exudative AMD under long-term therapy with anti-VEGF (Munk et al. 2016) . The aetiology of GA is not yet fully understood, and prognostic factors are still under discussion. Grading of GA lesions has been described previously by Bindewald et al. (2005) . In the early appearance of GA, the atrophic areas often tend to spare the foveal region, resulting in relatively normal central VA. However, an expansion of scotomas is inevitable, often yielding a foveal affection and complete central visual loss (Maguire & Vine 1986; Sarks et al. 1988; Schatz & McDonald 1989; Sunness 1999; Holz et al. 2014) . Hence, it is important to understand the pathophysiological pathways behind the disease in order to find novel treatment options, or at least to decelerate the expansion of atrophy.
Little is known about how MP changes during the progression of disease in patients with GA. What is known is that low MP levels are associated with existence of AMD, and MP levels can be increased by supplementation of lutein and zeaxanthin. As MP is described as a protective factor in AMD, an understanding of the association of MP with progression of disease may carry utility in ultimately preventing disease pathology (Lima et al. 2016) . Therefore, investigating MP in GA is of great importance.
The measurement of FAF intensity is an important tool for the diagnosis of GA. An increased FAF intensity with age is caused by an increase of retinal fluorophores, particularly lipofuscin (Delori et al. 1995) . Intensity of FAF signals declines at older ages, presumably due to phagocytosis of atrophic RPE cells (Delori et al. 2001) . New histological reports indicate that RPE cells extrude lipofuscin granules, and, therefore, show less autofluorescence (AF) intensity compared to neighbouring cells . In GA, FAF imaging may be of prognostic value, as increased retinal AF may be implicated in the development of the disease (Holz et al. 2001) . Optical coherence tomography (OCT) allows further grading and may be an additional helpful tool to image GA (Simader et al. 2014) .
Novel retinal imaging modalities might hold tremendous potential as they possibly contribute to our understanding of the pathophysiology underlying the development and progression of GA in AMD patients. Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a novel modality used to monitor FAF decay times, which may carry potential utility in imaging and thereby monitoring GA. Various diseases have been investigated with FLIO, including Alzheimer's disease, Stargardt disease, macular holes, diabetic retinopathy, central serous chorioretinopathy, retinal artery occlusion, choroideremia and GA (Jentsch et al. 2015; Dysli et al. 2015 Dysli et al. , 2016a Schweitzer et al. 2015; Sauer et al. 2017; Schmidt et al. 2017; Dysli et al. 2017a, b) . Previous studies on GA with FLIO focused on describing different FAF lifetime patterns in different phenotypes (Dysli et al. 2016a,b,c) . This study also describes the use of FLIO in GA; additionally, we further investigate the role of MP within different stages of the disease. In previous studies, we were able to demonstrate that short FAF decays in the macular region are caused by MP . Therefore, FLIO appears to provide a logical imaging modality for investigating the influence of MP in GA. This study was designed to take into account supplementation of lutein and describe differences in patients with and without supplementation. We also compare FAF lifetimes of different phenotypes of GA with each other. We are now able to take the entire area of GA in consideration and also separately investigated unaffected regions for comparison. Additionally, we investigated mean FAF lifetime of region at the border of GA. As Dysli et al. (2016a,b,c) reported previously, this novel diagnostic modality possibly holds a large prognostic potential in GA.
Patients and Methods
This prospective, cross-sectional study was approved by a local ethics committee and adhered to the tenets of the Declaration of Helsinki. Informed written consent was obtained from the patients prior to all investigations.
Subjects
Thirty-five eyes of 28 patients with GA were included in this study [17 females (60.7%), 11 males; mean age: 79.2 AE 8.0 years]. Nineteen (54.3%) of the investigated eyes were pseudophakic.
In GA, different patterns of FAF intensity and lifetimes can be found. As GA has previously been graded into nine subgroups, we followed this grading in our study (Bindewald et al. 2005; Dysli et al. 2016a,b,c) . Mean FAF decays were compared between those groups. Groups of GA were classified according to the extent of hyperfluorescence around the GA as follows: none (four eyes), focal (three eyes), diffuse (10 eyes), banded (six eyes) and patchy (12 eyes). Those cases categorized as diffuse were further subdivided into five groups: reticular (one eye), branching (one eye), fine granular (four eyes), trickling (three eyes), granular with peripheral punctual spots (one eye).
All patients were examined between July 2014 and March 2016 at the eye clinic of the University Hospital Jena. Upon review of the medical history of all potential cases, patients were excluded if they had undergone any eye surgery, except for uncomplicated cataract extraction. Patients with advanced cataracts in either eye and/ or ametropia higher than AE6 diopters were also excluded.
Procedure
All patients were examined by an ophthalmologist and diagnosed with GA secondary to non-exudative AMD prior to their inclusion in this study. The best corrected visual acuity (BCVA) was measured according to the decimal scale. The intra-ocular pressure was measured with a noncontact tonometer. In eyes with an intraocular pressure lower than 21 mmHg, pupils were dilated with tropicamide (0.5%; Mydriaticum Stulln Ò , Stulln, Germany) and neosynephrine (5%; Ursapharm, Saarbr€ ucken, Germany (Schweitzer et al. 2004; Becker 2014) . A pulsed diode laser (pulse frequency: 80 MHz; wavelength 473 nm; full width half maximum: 89 ps) excites FAF.
The FLIO set-up and laser safety have been described in detail previously (Schweitzer et al. 2004; Dysli et al. 2014 Dysli et al. , 2016a Sauer et al. 2015) . Briefly, FAF lifetime and intensity images are acquired from a 30°field centred at the fovea. Fluorescence photons are detected by two hybrid photo-multipliers (HPM-100-40; Becker&Hickl GmbH, Berlin, Germany), yielding results in two separate spectral channels: the SSC (498-560 nm) and the LSC (560-720 nm). Fluorescence in the LSC is dominated by lipofuscin. The spectral range was chosen according to previous studies conducted by our group (Schweitzer et al. 2007) . A high-contrast confocal infrared reflectance image for eye tracking is included to analyse fluorescence photons at their correct spatial location. A photon arrival histogram, which represents the probability density function of the decay process, is based on the detection of photons into 1024 time channels. Fluorescence lifetime imaging ophthalmoscopy (FLIO) has a time resolution of approximately 30 ps, based on the instrument response function (SSC: 172 ps, LSC 153 ps). To ensure reliable image quality, at least 1000 photons were recorded for each pixel within the atrophic region within the SSC as a minimal signal threshold.
The fluorescence data were analysed using the Software SPCIMAGE 4.4.2 (Becker&Hickl GmbH). By calculating the least-square fit of a series of three exponential functions, the fluorescence decay was approximated. A 5 9 5 pixel binning was used for the purpose of noise reduction. The amplitude weighted mean fluorescence decay time, s m , was used for further analysis. It represents the average of the three time constants from the fit, weighted by their amplitude. Further details have been described elsewhere (Becker 2014; Sauer et al. 2015) .
We investigated three areas of interest in each data set. First, the area of atrophy was identified by the presence of hypofluorescence in FAF intensity images and by OCT scans. Foveal sparing was defined as an island of intact retinal structure in the macular centre within an area of GA. We determined the shortest s m inside of the atrophic area and defined the border region as the area in which s m was up to 100 ps shorter than this value. Areas with even shorter s m were considered as healthy retina. Fluorescence lifetime imaging ophthalmoscopy (FLIO) images were then segmented using these two thresholds for s m . Figure 1 represents the areas, defined by this segmentation, from which mean lifetimes were obtained: (A) entire FAF image, (B) healthy/unaffected regions, (C) the border region and (D) the region of GA. For simplification, only the SSC is shown. The rectangle further defines these regions and serves the purpose of excluding long FAF lifetimes from the optical disc within the analysis of GA.
An average s m was obtained over the standardized Early Treatment Diabetic Retinopathy Study (ETDRS) grid. A circular area of the fovea/formerly fovea based on OCT images was characterized (diameter 1 mm, 'area C'). Of special interest were differences between area C and the atrophic area. These differences (s m of GA minus s m of area C) were correlated to the BCVA. The FLIMX software package was used for FAF lifetime analysis and for illustration of the FAF lifetimes . This software is documented and freely available for download online under the open source BSD-license (http://www.flimx.de).
Statistical analysis
For all statistical analyses, SPSS 21 (SPSS Inc., Chicago, IL, USA) was employed. To test for significant s m differences between regions in one eye, a t-test for paired samples was used. A t-test for independent samples was used to compare FAF lifetime means and VA between different groups of GA. A Pearson correlation was applied to investigate the relation of BCVA with s m differences. Data were reviewed for normal distribution. When data from the same regions were used in multiple tests, a Bonferroni correction was applied.
As the subgroups of GA were very small, no statistical analysis was performed on comparisons between subgroups.
Results

FAF lifetimes in GA
By comparing areas of GA to unaffected regions, we found that GA is reflected in changes of FAF lifetimes. Specifically, atrophic regions showed significantly longer decay times of 616 AE 343 ps (SSC) and 615 AE 226 ps (LSC) as compared to unaffected regions (SSC: 283 AE 127 ps; LSC: 333 AE 93 ps; p < 0.001 for both). Comparing GA regions to border regions further revealed that FAF lifetimes of GA were significantly longer than lifetimes of adjacent border region (p < 0.001 for LSC and SSC). Table 1 displays the mean FAF lifetimes over those regions as well as their range over all subjects. Figure 2 depicts typical FAF intensity and lifetime images of one eye with GA (both spectral channels are presented). A fundus photograph and an OCT image of this eye are also depicted in Fig. 2 .
A t-test comparison showed no significant differences in s m between the groups of phakic and pseudophakic subjects. This was investigated for the GA area, the border region, as well as unaffected regions.
Of the GA subgroups, horizontal cross sections of s m (SSC) through the area of GA show that s m at the central region increases in a steep manner at the border region of GA for the group 'focal', whereas the other groups show a more graduate increase of s m .
Heterogeneity of atrophic regions
Considerable variability in the FAF lifetime histograms was found within each area of GA, which reflects the heterogeneity of these regions. Taking all regions into account, the FAF lifetimes within the GA regions range from 262 to 2073 ps. The coefficient of variation (COV) of FAF lifetimes from each region is shown in Table 1 . In contrast to a small COV within unaffected regions (SSC: 6%, LSC: 7%), the GA regions showed a great diversity (SSC: 17%, LSC: 12%). Individual standard deviations of the atrophy in one eye of up to 309 ps were found, whereas the largest standard deviation within one eye in unaffected regions was 68 ps.
Foveal sparing
Figure 3 illustrates a comparison between three different modalities to characterize foveal sparing: OCT, FAF and FLIO. For the use of FLIO, previously characterized 'unaffected regions' were analysed with FLIMX as a horizontal 3D-projection instead of an en face image. Both, en face and horizontal 3D-projection are depicted in Fig. 3 . For simplification, only the SSC is shown. One eye with a spared fovea (A) and three eyes in which the macula was not spared (B-D) are shown. In FLIO images, a spared fovea can be determined by the presence of shortest s m at the foveal region (exact location determined by OCT). Those FAF lifetimes were shorter than those of unaffected areas adjacent to the atrophic lesions. They are shaped as a slim cone in the horizontal 3D projections. If this cone of foveal s m is not shorter than the rest of unaffected retina (eye B) or not present at all (eye C), the fovea is affected with atrophy. Additionally, in our study, four eyes showed short FAF lifetimes despite the absence of foveal sparing. However, none of the four eyes showed the characteristic slim cone of short s m ; mean FAF lifetimes were distributed rather broad and heterogeneously. These findings suggest that the substitution of a slim cone for one that appears broad and disintegrated (eye D) indicates that there is not foveal sparing. Sixteen (45.7%) eyes showed a spared fovea. Figure 1 (patient 2) depicts one eye where the fovea was spared, and Fig. 1 (patient 1) depicts one eye where the fovea was not spared.
Using the horizontal 3D projection of the software FLIMX, the difference in shape of short s m can be seen. In three other eyes with advanced foveal involvement, remnants of the cone of short s m can still be inferred, although the s m values in those regions were not shorter than the unaffected retina.
Supplementation of lutein
We further investigated the effect of lutein supplementation: 51.4% of the investigated eyes (17 eyes of 13 patients) were on long-term supplementation of lutein and zeaxanthin (>1 year, 10 mg lutein and 1 mg zeaxanthin daily), 48.6% (18 eyes of 15 patients) never took any supplementation. Of the 18 eyes without supplementation, only four eyes showed a spared fovea (22.2%). However, of the 17 eyes with supplementation, 12 eyes showed a spared fovea (70.6%). The rate of a spared fovea was three times higher in patients with supplementation. This is depicted in Fig. 4A ,B.
Visual acuity
Visual acuity (VA) was significantly better for patients with a spared fovea (mean BCVA 0.35) as compared to patients without foveal sparing (mean BCVA 0.12), p < 0.01. This is shown in Fig. 4C . However, in a few individual cases, the BCVA was as low as 0.05, even with a spared fovea. Within the subgroup analysis, the group 'focal' presented the lowest BCVA.
We investigated FAF lifetime differences between the atrophic area and the central area (C). For each individual eye, we calculated (s m of GA) minus (s m of area C) and correlated the difference to the VA, resulting in a significant Pearson correlation for the SSC (r = 0.38, p < 0.05) and a trend for the LSC (r = 0.33, p = 0.057; Fig. 5 ).
Discussion
This study investigates FAF lifetimes in GA, using FLIO instrumentation and the FLIMX software package for data analysis . This study gives hints on how FLIO may help to identify foveal sparing in conjunction with existing clinical imaging modalities OCT and FAF intensity imaging. Additionally, we were able to derive mean FAF lifetimes of different regions at the retina, especially of the region at the border or GA, which may be of prognostic value (Holz et al. 2001). To further understand the pathologies of GA, one focus of the investigation was set on the MP. As low MP levels can be increased by supplementation, certain aspects of the pathophysiology of GA concerning MP may be avoidable with supplementation. Lutein supplementation may protect the central macula, as seen in the considerably higher rate of foveal sparing in supplemented patients. However, as we do not know the foveal status at the beginning of supplementation, this effect can only be speculated. Nevertheless, investigating MP in GA carries great potential prognostic value.
FAF lifetimes in GA
These results indicate that FAF lifetimes in GA show characteristic patterns that appear to be in accordance with FAF intensity patterns. Similar findings have recently been described in detail by Dysli et al. (2016c) . Although our approaches for data analysis are slightly different from the aforementioned study, the results from both investigations are in good accordance. Our study confirms the data from the work of Dysli et al., particularly the finding of longer s m in atrophic areas. We speculate that prolonged s m in atrophic areas can be attributed to a loss of RPE and MP as well as an increase of connective tissue, for example in scars, containing collagen and elastin which are known to contribute to long FAF (Schweitzer et al. 2007; Schweitzer 2010) . Investigations of fluorescence lifetimes are usually complex. Nevertheless, FLIO is a very reproducible method to investigate FAF lifetime changes (Klemm et al. 2013; Dysli et al. 2014) . Independent of different fitting approaches, the patterns of FLIO are always similar within a disease and, thus, might give a clue to understand pathology from its molecular background (Schweitzer et al. 2007) .
Within the different GA subgroups, focal atrophy appears to have a large impact on FAF lifetimes as well as BCVA. The slope in which s m prolongs between healthy and affected areas might hold further prognostic information. The utility of these findings in prognosis should be evaluated in a larger study including more patients. Another major finding of the present work is that eyes with no hyperfluorescence around the GA show better BCVA as well as shorter FAF lifetimes than those without this same fluorescence pattern. The FAF lifetimes were significantly shorter for the GA as well as for area C. This may indicate that the hyperfluorescence surrounding the GA is of importance. In the present study, we analysed and began to characterize this hyperfluorescence within the border region. However, given the small number of patients, a reliable statement about how individual groups are affected can only be made with a larger number of patients.
Areas of interest
We found a great variability of lifetimes especially within the area of known GA. New histological studies report remaining RPE or RPE derived material within the atrophic zone (Zanzottera et al. 2015 (Zanzottera et al. , 2016 . This may explain the heterogeneity of FAF lifetimes within atrophic zones. Given these findings, when investigating GA, analysis of the entire region may carry more relevance than averaging or studying only a small representative region.
Based on setting cut-offs, it is possible to distinguish FAF decays separately from the entire GA area, the border region and unaffected retina. The mean FAF lifetimes of unaffected regions serve as reference values for each individual eye.
The region between GA and healthy regions has previously been called 'junctional zone', based on histological findings. Due to our low spatial resolution with FLIO, which does not allow us to identify individual RPE cells, we prefer not to use this term. The increased fluorescence lifetimes found in the border region might indicate that there are alterations within the RPE cells occurring in this area. Such alterations have also been found histologically: cells undergo apoptosis ('shedding'), with subsequent migration into the retina or migration under basal lamina deposits ('subducted cells') in this region (Zanzottera et al. 2015 (Zanzottera et al. , 2016 . Increased lifetimes, found here, point to changes in particular fluorophores, possibly suggesting the composition of lipofuscin, which remains indeterminate. However, these increased lifetimes in the border region might indicate pathologic alterations within the RPE. Lipofuscin is a mixture of alltrans retinal-derived compounds and oxidized/peroxidized lipids and lipoproteins whose composition shows remarkable differences across the fundus (Ablonczy et al. 2013) . The role of lipofuscin in the pathogenesis of AMD is still under debate. Further investigation of FAF lifetimes in areas of progressing disease may help to understand the implication of lipofuscin in the aetiology of AMD. Whether FAF lifetimes and patterns may predict areas of AMD progression needs further investigation in future longitudinal studies.
The FAF intensity of the border region of the GA has been reported to be of prognostic value (Holz et al. 2001) . Therefore, means to analyse FAF lifetimes of the border region are of great value and may be clinically useful in future. Whether FLIO, especially in the border region, can provide information on the GA progression, needs to be further evaluated. 
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Macular pigment and supplementation of lutein
As MP has been identified in prior work as the major contributor to short foveal AF lifetimes, we are able to describe MP in GA using FLIO . So far, little is known about the implication of MP within GA, as other measurements have proven difficult to perform due to patients' low VA or severe retinal changes caused by the atrophy. For this reason, no other measurement of MP with a different device than FLIO could be performed in this study. Recently, Dysli et al. (2016c) also independently suggested that MP is the source of short FAF lifetimes in GA. We agree and assume that FLIO is capable of monitoring changes of MP in GA. The present study revealed that if atrophic lesions spare the fovea, MP remains as a slim cone at the spared region (Fig. 3A) . Although we have no longitudinal data, our investigation of different stages of GA supports the notion that the atrophy progresses over time. In early stages, the slim cone appears to lose its shape, perhaps due to gradual disintegration. In intermediate stages, we observe how short FAF lifetimes change to an unshaped cluster, similar to what we have shown in Fig. 3D . In eyes with clinically progressed disease stages, further changes in FAF decays are found. In some cases, FAF lifetimes prolonged severely (Fig. 3B,C) . From these findings, we can infer that the first step in progression is degeneration of RPE cells. Subsequently, the MP seems to diminish, which may be due to the retinal disintegration. This is supported by finding remnants of the short FAF lifetime cone within progressed foveal involvement. Dysli and coworkers also described remnants of short FAF lifetimes in the fovea of some eyes with GA (Dysli et al. 2016c ). It could be argued that these short FAF lifetimes are caused by different fluorophores related to the photoreceptors or their underlying RPE. However, due to the remaining presence of the short FAF lifetimes in cases with low VA, we think that the short fluorescence decay times are not solely attributed to the photoreceptors. Dysli et al. 2016c also described the rare foveal occurrence of short AF lifetimes in cases with foveal involvement of GA, these could be such remnants of the MP. Nevertheless, this is only hypothesized from different appearance of lifetime distributions in our cross-sectional study and difficult to prove without longitudinal data. For the same reason, we cannot predict which time it takes for MP to decay.
In further speculating on the impact of MP on GA pathophysiology, we suspect that MP may be involved in maintaining integrity at the fovea and may contribute to the preservation of VA. This is supported by the fact that our cohort of patients who took supplementation were found to have evidence of foveal sparing three times more often than the cohort which did not take supplementation. Unfortunately, as we do not know about the foveal status of these patients at the beginning of supplementation, at this time we can only speculate about the foveal protection of supplementation. Some patients in the supplementation group were found to have regions of GA that affected the fovea; whether this occurred before or after the initiation of supplementation is still unknown. Foveal sparing through supplementation is not guaranteed, although these results do suggest that high MP values, for example due to supplementation, may reduce the risk of foveal atrophy when GA develops.
Foveal sparing
Investigating the foveal region carries great importance, as initially GA often tends to spare this regions (Maguire & Vine 1986; Sarks et al. 1988; Schatz & McDonald 1989; Sunness 1999; Holz et al. 2014) . One may question if age influences foveal sparing, which we did not find. In fact, the patient group with foveal sparing was 2.3 years older than the group with foveal atrophy.
Investigating foveal sparing with FAF can sometimes be difficult. In contrast, FLIO provides a possible alternative means to define foveal sparing. This study presents a novel approach to this characterization. Prior FLIO studies have only analysed en face images. In this study, we used horizontal 3D projections of s m to search for a spared fovea, based on the fact that shortest s m is related to the MP. A slim cone of short AF lifetimes at the fovea indicates sparing. As described previously and confirmed by this study, remnants of MP may remain in the retina even if the fovea is atrophic (Dysli et al. 2016c ). Based on our previous studies, we can exclude that this short FAF lifetime within the macular centre is caused by remnants of the RPE, as the RPE shows longer FAF decays . Attention is therefore required, yet MP fluorescence in atrophic foveae does not present itself as a slim cone but rather as a larger heterogeneous region. Presently, the analysis of FAF lifetimes demonstrated in this study provides hints towards foveal sparing and might therefore be useful. Until hard criteria are defined for the use of FLIO in foveal sparing, OCT and FAF images also must be consulted.
Visual acuity
The BCVA does not always correlate with the size of GA and central regions may be spared (Sarks et al. 1988) . Therefore, when investigating VA, we did not focus on individual AF lifetimes at the GA or fovea. We found a significant correlation of the lifetime differences (GA minus fovea) to the VA in the SSC and an almost-significant trend in the LSC. This is in agreement with Dysli et al. (2016c) and indicates that FAF lifetimes can in fact be correlated with the VA. A larger difference in AF lifetimes between the atrophic area and the central area indicates that the central area is less affected. This often results in a better VA. Nevertheless, in some cases, the BCVA was low even with foveal sparing. There may be other reasons, for example cataract, various retinal diseases or simply the attention of the patient, that explain this low VA. If the fovea is strongly affected, FAF lifetimes of area C may be as long or even longer than that of the entire GA area (negative difference, shows advanced atrophy within the fovea).
Limitations
The small number of investigated eyes represents the greatest limitation, especially when investigating subgroups of GA. Remarks about characteristics of GA subgroups were only reported as observations; no statistical analysis was performed. Additionally, in patients with a mean age of 79 years, an influence of other diseases, for example diabetes or high blood pressure, may be present. This was not further investigated. Best corrected visual acuity (BCVA) may also be affected by other diseases than simply AMD/GA. This may explain low VA in some eyes with a spared fovea. Although we excluded patients with advanced cataract, we do not know whether the BCVA might be limited by minor cataracts in some patients.
As no significant differences of s m between phakic and pseudophakic eyes were found, we inferred that the differences caused by the disease must outweigh the impact from differences among different lenses. Additionally, even disregarding the lens status, highly significant differences between areas of interest were found. Furthermore, our investigation of differences in FAF lifetimes within the same patient is largely lens independent.
Finally, we have no follow-up investigations yet. Until further longitudinal studies with larger cohorts can be carried out, we can only speculate about long-term changes and prognostic values.
Conclusions
Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a new imaging method to monitor GA. We present an easy and reproducible way to analyse FAF lifetimes in GA using FLIO data. We use the software FLIMX, which is a suitable program for analysis of FLIO, to describe FAF lifetime changes in GA. Additionally, FLIMX allows us to distinguish between areas of interest with high contrast. It is possible to analyse FAF lifetimes of the entire area of GA, the border region of GA, unaffected regions and -if present -an intact macula. These results also indicate that FLIO may give hints towards foveal sparing. Future studies are needed to further characterize changes within the border region besides the atrophy over time. This may give additional information on the involvement of certain fluorophores in the pathogenesis of GA. By analysing the three-dimensional shape of short FAF decays, presumably caused by MP, we might be able to analyse changes within the MP in GA in future studies.
